USD 30.99 billion
HIV Drugs Market Size, Share, Growth Analysis, By Medication Class(Multi-Class Combination Drugs (Atripla, Complera, Prezcobix, Stribild), By Distribution Channel(Hospital Pharmacies, Drugs stores and retail pharmacies, Online pharmacies), By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35I2310 |
Region:
Global |
Published Date: October, 2024
Pages:
219
|Tables:
71
|Figures:
69
HIV Drugs Market Insights
HIV Drugs Market size was valued at USD 34.57 Billion in 2023 and is poised to grow from USD 37.82 Billion in 2024 to USD 77.6 Billion by 2032, growing at a CAGR of 9.4% during the forecast period (2025-2032).
Growing prevalence of HIV infections around the world are slated to bolster the sales of HIV drugs going forward. Increasing awareness regarding HIV infections and growing demand for better treatment and therapeutics for the same is also estimated to uplift the demand for HIV drugs in the future. Advancements in antiretroviral therapy (ART) for the treatment of HIV infections are also expected to play a crucial role in augmenting the global HIV drugs market outlook over the coming years. High investments in the development of better HIV treatments are also estimated to create an opportune setting for HIV drug providers going forward. Launch of new HIV awareness and prevention initiatives by governments and public health organizations is also estimated to boost the sales of HIV drugs in the long run. Rising emphasis on early testing and diagnostics for HIV infections is also expected to create new business scope for HIV drug companies through 2031 and beyond. However, side effects and toxicity in long-term treatments, issues of drug resistance, social stigma and discrimination against HIV patients, and high cost of certain drugs are some key constraints for HIV drugs demand outlook.
Market snapshot - 2024-2031
Global Market Size
Largest Segment
Dust collectors
Fastest Growth
Dust collectors
Growth Rate
4.10% CAGR
Global HIV Drugs Market ($ Bn)
Country Share for Europe Region (%)
To get more reports on the above market click here to Buy The Report
HIV Drugs Market Segmental Analysis
Global HIV Drugs Market is segmented by Medication Class, Distribution Channel. Based on Medication Class, the market is segmented into Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Entry Inhibitors, HIV Integrase Strand Transfer Inhibitors, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drugs stores and retail pharmacies, Online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.
Analysis by Medication Class
Combination HIV medicines are estimated to hold a major part of the global HIV drugs market share going forward. Growing efforts to improve HIV medication management and reduce the risk of potential side effects and cross infections are expected to help this segment maintain its dominance in the future. Low risk of drug resistance through the use of combination HIV medicine is also a key benefit helping this segment bring in more revenue than others over the coming years. Use of combination HIV medications can also help prevent the transmission of disease from one person to another, this is especially useful to prevent transmission of HIV from pregnant mothers to their offspring.
Meanwhile, integrase inhibitors are slated to hold the second-largest HIV drugs market share over the coming years. Standard use of integrase inhibitors in the treatment of any HIV infection and their low risk of side effects allows this segment to offer lucrative opportunities for all HIV drugs providers going forward. Extensive use of integrase inhibitors in initial HIV treatment will also create new business scope for market players through 2031 and beyond. Raltegravir (Isentress), elvitegravir (Vitekta), dolutegravir (Tivicay), bictegravir (Bictarvy), and cabotegravir (Vocabria) are some popular integrase inhibitors used extensively in HIV treatment and management.
Analysis by Distribution Channel
Hospital pharmacies are projected to spearhead the global HIV drugs market forecast in the future. Growing hospitalization of patients suffering from HIV and increasing availability of novel HIV treatments in hospitals are slated to create new business scope for market players via this segment going forward. High availability of novel HIV drugs and provision of specialized services by hospital pharmacies are also helping this segment hold sway over others. Moreover, the availability of HIV drugs at subsidized prices and increasing number of prescription-only HIV drugs are also expected to help this segment generate more revenue for all market players in the long run.
Meanwhile, the demand for HIV drugs from online pharmacies is slated to rise at an impressive pace in the future. Increasing adoption of telehealth and telemedicine practices in HIV treatment and management will help this segment generate new business scope for HIV drug providers going forward. Increasing internet penetration and the growing preference of patients to buy drugs at their own convenience is also expected to help offer lucrative new opportunities for HIV drug providers in the future. Increasing availability of new online pharmacy platforms is also expected to help this segment offer new revenue generation potential for all market players through 2031 and beyond.
Global HIV Drugs Market By Product
To get detailed analysis on other segments, Request For Free Sample Report
HIV Drugs Market Regional Insights
North America is estimated to emerge as the leader in terms of HIV drugs demand owing to high prevalence of HIV infections in this region. Rising awareness regarding HIV infections, presence of a developed healthcare infrastructure, and presence of key HIV drug suppliers are all contributing to the dominance of this region in terms of HIV drugs market size and volume. Canada and the United States are slated to be the most opportune markets for HIV drug providers operating in North America. High investments in medical R&D in this region also help boost the sales of HIV drugs going forward.
Increasing number of HIV patients, growing awareness regarding HIV and other chronic diseases, and growing demand for HIV treatment are slated to help Asia Pacific become the most opportune market for HIV drugs companies. Supportive government initiatives to improve accessibility to proper HIV treatment will also be a key HIV drugs market trend promoting sales of HIV drugs in this region. India and China are estimated to be the top markets for any HIV drugs company looking to make a mark in this region through 2031 and beyond. Increasing healthcare spending potential of patients will also positively impact the demand for HIV drugs in the future.
Global HIV Drugs Market By Region
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
HIV Drugs Market Dynamics
Market Drivers
Support and Awareness Programs
- Governments and public health organizations are launching new support and awareness initiatives to help promote the treatment of HIV infections. Such programs are expected to improve accessibility to HIV drugs for patients around the world and this is expected to especially benefit people in low to middle income countries going forward.
High Incidence of HIV Infections
- The prevalence of HIV infections has increased rapidly around the world, and this is a key factor promoting the sales of HIV drugs. Growing awareness and rising testing are also contributing to a greater number of people being identified for positive HIV infections thereby also benefiting the global HIV drugs market growth in the long run.
Restraints
Issues of Drug Resistance
- Drug resistance has emerged as a key issue for all of modern medicine and is a key constraint for HIV drugs market forecast as well. Inconsistent adherence to medication is a major cause for drug resistant HIV strains. This issue of drug resistance limits treatment options, complicates management and necessitates the development of alternative therapies and slows down overall market development potential.
Toxicity and Side Effects in Long Term Treatment
- HIV infections often require long-term treatments, and this could lead to potential side effects and high toxicity over time. Metabolic disorders, cardiovascular effects, and liver and kidney toxicity are some key side effects that could hamper the sales of HIV drugs going forward. This could lead to hesitance among patients and further hurt the demand outlook.
Request Free Customization of this report to help us to meet your business objectives.
HIV Drugs Market Competitive Landscape
HIV drug providers are expected to focus on collaborations and partnerships to widen their business scope and increase sales going forward. Teaming up with governments and public health organizations could also improve the accessibility of HIV drugs to more patients in the future. Targeting underdeveloped and developing countries is forecasted to present lucrative money-making opportunities for HIV drug providers in the long run. Gaining approvals for their novel drugs will also be a key area of interest for all market players.
Top Player’s Company Profiles
- Gilead Sciences, Inc. (US)
- AbbVie Inc. (US)
- Bristol-Myers Squibb Company (US)
- Johnson & Johnson (US)
- GlaxoSmithKline plc (UK)
- Teva Pharmaceutical Industries Ltd. (Israel)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Merck & Co., Inc. (US)
- Boehringer Ingelheim International GmbH (Germany)
- Cipla Ltd. (India)
- ViiV Healthcare (UK)
- AstraZeneca plc (UK)
- Hikma Pharmaceuticals PLC (UK)
- Abbott Laboratories (US)
- Eli Lilly and Company (US)
- Alvogen (US)
- Aurobindo Pharma (India)
- Mundipharma (Switzerland)
- Sanofi S.A. (France)
- Novartis AG (Switzerland)
- Dr. Reddy's Laboratories (India)
- Zydus Cadila (India)
- Perrigo Company plc (Ireland)
Recent Developments
- In August 2023, Aurobindo Pharma Ltd., a leading Indian multinational pharmaceutical company announced the launch of its new HIV triple combination product. The company obtained a pediatric dolutegravir voluntary license to develop and supply this novel drug for children affected with HIV in around 123 low to middle income countries.
- In February 2022, ViiV Healthcare, a leading name in the HIV treatment market announced the approval of Cabenuva by the United States Food and Drug Administration (FDA). This approval helped the company strengthen its stance in the long-acting treatment space for HIV-1 in virologically suppressed adults.
- In December 2021, the U.S. FDA announced the approval of the first injectable HIV treatment for pre-exposure prevention in at-risk adults and adolescents. Apretude was intended to reduce the risk of sexual transmission of HIV and also eliminates the need for daily pills for HIV prevention and management.
HIV Drugs Key Market Trends
- Dual Therapy for HIV Treatment: HIV drug companies can focus on the dual therapy trend to maximize their business scope and overcome the restraint of side effects caused by HIV drugs. Reduced toxicity and pill consumption burden are other benefits offered by dual therapy thereby making this a prominent HIV drugs market trend for all companies to focus on going forward.
- Integration of Digital Health: HIV drug providers can focus on integrating digital health in their offerings to improve medication adherence among patients. Growing emphasis on better patient engagement and value-based care model adoption are also estimated to create new opportunities for HIV drug companies as per this HIV drugs market analysis.
HIV Drugs Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, growing incidence of HIV infections around the world and launch of new awareness and accessibility programs for HIV drugs are slated to drive market development going forward. However, risk of side effects and toxicity and drug resistance are slated to impede sales of HIV drugs in the future. North America is slated to be the leading market for HIV drugs companies owing to the high incidence of HIV among people in countries such as the United States and Canada. Integration of digital health and use of dual therapy are estimated to offer lucrative opportunities for HIV drugs providers in the long run.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 31.6 billion |
| Market size value in 2031 | USD 70.93 billion |
| Growth Rate | 9.4% |
| Base year | 2023 |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on HIV Drugs Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on HIV Drugs Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the HIV Drugs Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the HIV Drugs Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the HIV Drugs Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the HIV Drugs Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
